Use of biologics in pouchitis a systematic review

Journal of Clinical Gastroenterology

Volumn 49, Issue 8, 2015, Pages 647-654

  Herfarth, Hans H ^a   Long, Millie D ^a   Isaacs, Kim L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Anti TNF therapy; Biologics; Inflammatory bowel disease; Infliximab; Pouchitis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; TUMOR NECROSIS FACTOR;

ANTIBIOTIC THERAPY; BACTERIAL FLORA; BIOLOGICAL THERAPY; CAPSULE ENDOSCOPY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE REGISTRY; FAMILIAL COLON POLYPOSIS; FOLLOW UP; HUMAN; ILEITIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COMPLICATION; CROHN DISEASE; IMMUNOLOGY; POUCHITIS;

ADALIMUMAB; BIOLOGICAL PRODUCTS; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; INTEGRINS; POUCHITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942518976     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000367     Document Type: Review

References (71)

1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
2. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103:1998-2006.
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
4. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a populationbased cohort study. Am J Gastroenterol. 2009;104:2080-2088.
5. Allison J, Herrinton LJ, Liu L, et al. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008;6:999-1003.
6. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
7. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234-239.
8. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856-1860.
9. Romanos J, Samarasekera DN, Stebbing JF, et al. Outcome of 200 restorative proctocolectomy operations: the John Radcliffe Hospital experience. Br J Surg. 1997;84:814-818.
10. Svaninger G, Nordgren S, Oresland T, et al. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol. 1993;28:695-700.
11. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333-340.
12. Coffey JC, McCarthy E, Kavanagh E, et al. Pouchitis: an evolving clinical enigma-a review. Dis Colon Rectum. 2009; 52:140-153.
13. Shen B, Fazio VW, Remzi FH, et al. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:2796-2807.
14. Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013-1023.
15. Wu H, Shen B. Pouchitis and pouch dysfunction. Med Clin North Am. 2010;94:75-92.
16. Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol. 2004;38:S44-S50.
17. Shen B. Acute and chronic pouchitis-pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol. 2012;9:323-333.
18. Lim M, Adams JD, Wilcox M, et al. An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota. Dis Colon Rectum. 2009;52:1492-1500.
19. Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008;14:858-867.
20. Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007;5:352-360.
21. Duffy M, O'Mahony L, Coffey JC, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum. 2002; 45:384-388.
22. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatmentresistant pouchitis. Aliment Pharmacol Ther. 1999;13:713-718.
23. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum. 2007;50:498-508.
24. Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13: 1250-1255.
25. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193-1196.
26. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909-917.
27. Gionchetti P, Amadini C, Rizzello F, et al. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol. 2003;17:821-831.
28. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology. 2003;124:1202-1209.
29. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22: 721-728.
30. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-2082.
31. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119:305-309.
32. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
33. Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther. 2002;16:27-34.
34. Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol. 2004;99:1527-1531.
35. Miglioli M, Barbara L, Di Febo G, et al. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. N Engl J Med. 1989;320:257.
36. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc. 1993;68:978-981.
37. Tremaine W, Sandborn WJ, Kenan ML. Bismuth subsalicylate tablets for chronic antibiotic-resistant pouchitis. Gastroenterology. 1998;114(suppl 1):A1101.
38. Belluzzi A, Serrani M, Roda G, et al. Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Aliment Pharmacol Ther. 2010;31:228-232.
39. Shen B, Pardi DS, Bennett AE, et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol. 2009;104:1468-1474.
40. Joelsson M, Andersson M, Bark T, et al. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebocontrolled double-blind study. Scand J Gastroenterol. 2001;36: 1179-1184.
41. Tremaine WJ, Sandborn WJ, Wolff BG, et al. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 1997;11:1041-1046.
42. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002;45:621-627.
43. Lovegrove RE, Tilney HS, Heriot AG, et al. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis Colon Rectum. 2006;49:1293-1306.
44. Shen B, Lashner B. Can we immunogenotypically and immunophenotypically profile patients who are at risk for pouchitis? Am J Gastroenterol. 2004;99:442-444.
45. Yanai H, Ben-Shachar S, Baram L, et al. Gene expression alterations in ulcerative colitis patients after restorative proctocolectomy extend to the small bowel proximal to the pouch. Gut. 2015;64:756-764.
46. Haveran LA, Sehgal R, Poritz LS, et al. Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA. Dis Colon Rectum. 2011;54:15-20.
47. Melton GB, Fazio VW, Kiran RP, et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Ann Surg. 2008;248:608-616.
48. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679-685.
49. Colombel JF, Ricart E, Loftus EV Jr, et al. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98:2239-2244.
50. Calabrese C, Gionchetti P, Rizzello F, et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther. 2008;27:759-764.
51. Shen B, Remzi FH, Lavery IC, et al. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment Pharmacol Ther. 2009;29:519-526.
52. Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16:243-249.
53. Barreiro-de Acosta M, Garcia-Bosch O, Souto R, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis. 2012;18:812-817.
54. Li Y, Lopez R, Queener E, et al. Adalimumab therapy in Crohn's disease of the ileal pouch. Inflamm Bowel Dis. 2012;18:2232-2239.
55. Ricart E, Panaccione R, Loftus EV, et al. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999;117:429-432.
56. Viscido A, Habib FI, Kohn A, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther. 2003;17:1263-1271.
57. Kooros K, Katz AJ. Infliximab therapy in pediatric Crohn's pouchitis. Inflamm Bowel Dis. 2004;10:417-420.
58. Mohanty SP, Darling A, Isaacs KL. Management of pouchitis of the ileoanal pouch with infliximab. Gastroenterology. 2004;126:A631.
59. Molnar T, Farkas K, Nagy F, et al. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report. Inflamm Bowel Dis. 2008;14:1752-1753.
60. Yeates J, Rashid M. Successful long-term use of infliximab in refractory pouchitis in an adolescent. Gastroenterol Res Pract. 2010;2010:860394.
61. Akitake R, Nakase H, Tamaoki M, et al. Modulation of Th1/ Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis. Dig Dis Sci. 2010;55:1781-1784.
62. Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol. 2012;24:756-758.
63. Viazis N, Giakoumis M, Koukouratos T, et al. One-year infliximab administration for the treatment of chronic refractory pouchitis. Ann Gastroenterol. 2011;24:290-293.
64. Viazis N, Giakoumis M, Koukouratos T, et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis. 2013;7:457-460.
65. Alvarez A, Maric L, Schneider A. A rare case of collagenous pouchitis treated with adalimumab. Am J Gastroenterol. 2014;109:S438.
66. Iizuka M, Etou T, Yagisawa H, et al. One year of infliximab therapy successfully improved a case of refractory pouchitis without the use of antibiotics. Intern Med. 2014;53:2581-2583.
67. Shen B, Achkar JP, Connor JT, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46:748-753.
68. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409-415.
69. Semb S, Nordgaard-Lassen I. Treatment of fistulating pouchitis with tumour necrosis factor-alpha-inhibitor (infliximab). Ugeskr Laeger. 2008;170:4134-4135.
70. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
71. Cozijnsen MA, Escher JC, Griffiths A, et al. Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:951-961.